<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="as the COVID-19 resource centre remains active. Abstract Aim Coronavirus" exact="disease" post="2019 (COVID-19) is a novel highly contagious infection caused"/>
 <result pre="Aim Coronavirus disease 2019 (COVID-19) is a novel highly contagious" exact="infection" post="caused by SARS-CoV-2, which has been became a global"/>
 <result pre="hyper-inflammatory immune response in critically ill patients, which leads to" exact="acute" post="respiratory distress syndrome (ARDS) and multi-organ failure. Material and"/>
 <result pre="immune response in critically ill patients, which leads to acute" exact="respiratory" post="distress syndrome (ARDS) and multi-organ failure. Material and methods"/>
 <result pre="in critically ill patients, which leads to acute respiratory distress" exact="syndrome" post="(ARDS) and multi-organ failure. Material and methods A literature"/>
 <result pre="up to April 30, 2020. The search resulted in 361" exact="total" post="articles. After reviewing the titles and abstracts for inclusion,"/>
 <result pre="damage and even death. Graphical abstract Keywords COVID-19 Immune system" exact="Acute respiratory distress syndrome" post="Hyperinflammation Cytokine storm 1 Introduction Severe acute respiratory syndrome"/>
 <result pre="and even death. Graphical abstract Keywords COVID-19 Immune system Acute" exact="respiratory" post="distress syndrome Hyperinflammation Cytokine storm 1 Introduction Severe acute"/>
 <result pre="death. Graphical abstract Keywords COVID-19 Immune system Acute respiratory distress" exact="syndrome" post="Hyperinflammation Cytokine storm 1 Introduction Severe acute respiratory syndrome"/>
 <result pre="system Acute respiratory distress syndrome Hyperinflammation Cytokine storm 1 Introduction" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus"/>
 <result pre="Acute respiratory distress syndrome Hyperinflammation Cytokine storm 1 Introduction Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease"/>
 <result pre="respiratory distress syndrome Hyperinflammation Cytokine storm 1 Introduction Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease 2019"/>
 <result pre="distress syndrome Hyperinflammation Cytokine storm 1 Introduction Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) causes the coronavirus disease 2019 (COVID-19),"/>
 <result pre="Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus" exact="disease" post="2019 (COVID-19), and has affected people's lives globally, since"/>
 <result pre="[1,2]. The main route of virus entry and transmission is" exact="respiratory" post="droplets that are expelled and absorbed by the mucous"/>
 <result pre="spectrum of COVID-19 varies from an asymptomatic form to severe" exact="respiratory" post="failure (SRF) that necessitates mechanical ventilation and support in"/>
 <result pre="intensive care unit (ICU) and can lead to multi-organ failure." exact="Pneumonia" post="is the most frequent serious manifestation of COVID-19, characterized"/>
 <result pre="symptoms are headaches, sore throat, and rhinorrhea. In addition to" exact="respiratory" post="symptoms, gastrointestinal symptoms, myalgia, skin rashes, and neurological involvement"/>
 <result pre="21st century; one named SARS-CoV and the other Middle East" exact="Respiratory" post="Syndrome (MERS). Coronaviruses are large enveloped viruses with a"/>
 <result pre="century; one named SARS-CoV and the other Middle East Respiratory" exact="Syndrome" post="(MERS). Coronaviruses are large enveloped viruses with a positive"/>
 <result pre="the S2 domain is responsible for virus-cell membrane fusion and" exact="viral" post="entry with higher affinity [7]. Higher expression of the"/>
 <result pre="compared to children may be a reason for the higher" exact="infection" post="rate seen in adults [8,9]. Another noteworthy point is"/>
 <result pre="[13,14]. ACE2 is highly expressed in some organs, like lung" exact="epithelial" post="cells, especially type II pneumocytes, and in cells of"/>
 <result pre="highly expressed in some organs, like lung epithelial cells, especially" exact="type II" post="pneumocytes, and in cells of the heart, kidneys, gastrointestinal"/>
 <result pre="the virus. Following entry of SARS-CoV-2 into the cell, the" exact="viral" post="RNA genome is transferred from the envelope into the"/>
 <result pre="the translation process begins. After replication of the RNA new" exact="viral" post="particles are formed, by incorporating part of the host"/>
 <result pre="incorporating part of the host cell membrane in the new" exact="viral" post="envelope. Although, SARS-CoV-2 buds from the infected cell, it"/>
 <result pre="cell, it does not lyse it directly [17]. Infected lung" exact="epithelial" post="cells produce interleukin IL-8 which acts as a chemoattractant"/>
 <result pre="[18]. The innate immune response is initially triggered by lung" exact="epithelial" post="cells, alveolar macrophages and neutrophils. In the next stage,"/>
 <result pre="immune responses are triggered involving T and B lymphocytes to" exact="complete" post="the complete immune response [19]. Virus particles containing single-stranded"/>
 <result pre="are triggered involving T and B lymphocytes to complete the" exact="complete" post="immune response [19]. Virus particles containing single-stranded ssRNA, act"/>
 <result pre="leads to increased secretion of pro-inflammatory cytokines, like IL-1, IL-6," exact="monocyte" post="chemo attractant protein-1 (MCP-1), MIP-1A, tumor necrosis factor Î±"/>
 <result pre="cytokines, like IL-1, IL-6, monocyte chemo attractant protein-1 (MCP-1), MIP-1A," exact="tumor" post="necrosis factor Î± (TNF-Î±) and ultimately interferon 1 (IFN1)"/>
 <result pre="been reported that IL-17 expression is correlated with several inflammatory" exact="respiratory" post="diseases [23]. All these immune signaling pathways are designed"/>
 <result pre="research into SARS-CoV and MERS, which previously caused epidemics of" exact="acute" post="respiratory syndromes. In this short duration of the present"/>
 <result pre="into SARS-CoV and MERS, which previously caused epidemics of acute" exact="respiratory" post="syndromes. In this short duration of the present pandemic,"/>
 <result pre="which previously caused epidemics of acute respiratory syndromes. In this" exact="short" post="duration of the present pandemic, studies have shown that"/>
 <result pre="other hand, the effectiveness of the innate immune response against" exact="viral infection" post="depends mainly on IFN1 production and its downstream signaling"/>
 <result pre="hand, the effectiveness of the innate immune response against viral" exact="infection" post="depends mainly on IFN1 production and its downstream signaling"/>
 <result pre="IFN1 production and its downstream signaling that results in controlling" exact="viral" post="replication and induction of an adequate adaptive immune response"/>
 <result pre="due to the complex immune dysregulation caused by this infection." exact="Chronic" post="stimulation of T cells, resulting in a cytokine storm"/>
 <result pre="defenses and puts the patient in a dangerous situation. High-grade" exact="chronic" post="viral infections result in CD8+ T cell exhaustion (Tex)"/>
 <result pre="and puts the patient in a dangerous situation. High-grade chronic" exact="viral" post="infections result in CD8+ T cell exhaustion (Tex) leading"/>
 <result pre="puts the patient in a dangerous situation. High-grade chronic viral" exact="infections" post="result in CD8+ T cell exhaustion (Tex) leading to"/>
 <result pre="cell exhaustion (Tex) leading to a decreased effector function and" exact="lower" post="proliferative capacity. Tex leads to over-expression of inhibitory receptors,"/>
 <result pre="IL-6, and the relevant subset of lymphocytes [26]. Overall, general" exact="lymphopenia" post="is seen in COVID-19 patients, especially in severe cases"/>
 <result pre="seen in COVID-19 patients, especially in severe cases [27,28]. 2.4" exact="Disease" post="in some particular groups of patients Similar to all"/>
 <result pre="Disease in some particular groups of patients Similar to all" exact="infectious diseases," post="the immune system plays an essential role in virus"/>
 <result pre="been enough scientific evidence to generally employ immunosuppressive drugs in" exact="autoimmune diseases" post="like rheumatoid arthritis (RA) [30,31]. On the other hand,"/>
 <result pre="evidence to generally employ immunosuppressive drugs in autoimmune diseases like" exact="rheumatoid arthritis" post="(RA) [30,31]. On the other hand, the hyper-inflammatory and"/>
 <result pre="to generally employ immunosuppressive drugs in autoimmune diseases like rheumatoid" exact="arthritis" post="(RA) [30,31]. On the other hand, the hyper-inflammatory and"/>
 <result pre="[30,31]. On the other hand, the hyper-inflammatory and cytokine release" exact="syndrome" post="(CRS) typical of COVID-19 causes tissue damage to the"/>
 <result pre="in the ICU [33]. Another high-risk group for COVID-19 is" exact="cancer" post="patients, who are administered cytotoxic drugs. Although their immune"/>
 <result pre="and increased mortality in patients with underlying diseases (such as" exact="hypertension" post="and diabetes) has been proven [34]. Diabetes mellitus type"/>
 <result pre="diseases (such as hypertension and diabetes) has been proven [34]." exact="Diabetes mellitus" post="type II can include a hyperinflammatory state with a"/>
 <result pre="as hypertension and diabetes) has been proven [34]. Diabetes mellitus" exact="type II" post="can include a hyperinflammatory state with a low-grade inflammatory"/>
 <result pre="that causes severe instability in the blood glucose levels of" exact="diabetes" post="patients, which worsens the inflammatory imbalance [37]. As a"/>
 <result pre="enzymes and inflammatory cytokines compared to nondiabetic individuals with COVID-19" exact="pneumonia" post="[38]. 3 The immune system as a foe 3.1"/>
 <result pre="red blood cell (RBC) receptor for the parasite that causes" exact="malaria" post="in humans, and is a transmembrane protein of the"/>
 <result pre="Its expression is induced in several conditions such as asthma," exact="cancer" post="stem cells, high glucose concentration in monocytes, and inflammatory"/>
 <result pre="itself could be an entryway for SARS-CoV-2. 3.2 Macrophage activation" exact="syndrome" post="and the cytokine storm Patients with COVID-19 have increased"/>
 <result pre="[42]. The cytokine storm (CS) is typical of macrophage activation" exact="syndrome" post="(MAS) or secondary hemophagocytic lymphohistiocytosis (sHLH). Consequently, tissue damage,"/>
 <result pre="storm (CS) is typical of macrophage activation syndrome (MAS) or" exact="secondary" post="hemophagocytic lymphohistiocytosis (sHLH). Consequently, tissue damage, lung injury and"/>
 <result pre="(CS) is typical of macrophage activation syndrome (MAS) or secondary" exact="hemophagocytic lymphohistiocytosis" post="(sHLH). Consequently, tissue damage, lung injury and acute respiratory"/>
 <result pre="secondary hemophagocytic lymphohistiocytosis (sHLH). Consequently, tissue damage, lung injury and" exact="acute" post="respiratory distress syndrome (ARDS) could be expected [43]. Furthermore,"/>
 <result pre="hemophagocytic lymphohistiocytosis (sHLH). Consequently, tissue damage, lung injury and acute" exact="respiratory" post="distress syndrome (ARDS) could be expected [43]. Furthermore, a"/>
 <result pre="(sHLH). Consequently, tissue damage, lung injury and acute respiratory distress" exact="syndrome" post="(ARDS) could be expected [43]. Furthermore, a study showed"/>
 <result pre="could be expected [43]. Furthermore, a study showed that the" exact="peripheral" post="blood of a patient with severe COVID-19 had a"/>
 <result pre="of Th17 cells, which secrete IL-17, and are associated with" exact="autoimmune" post="and inflammatory diseases. In the mucosal immune response, IL-22,"/>
 <result pre="COVID-19 patients [44]. All of the above-mentioned factors result in" exact="pneumonia" post="and ARDS, besides hyper-ferritinemia, coagulopathy, and multi-organ failure in"/>
 <result pre="of aggressive tissue-damaging immune responses via increased IL-6 secretion, and" exact="secondary" post="CS leads to a general picture of hyper-inflammatory immunodeficiency,"/>
 <result pre="general picture of hyper-inflammatory immunodeficiency, are all in line with" exact="primary" post="HLH. This is important in terms of the viral"/>
 <result pre="with primary HLH. This is important in terms of the" exact="viral" post="load, because of the correlation between the RNA viral"/>
 <result pre="the viral load, because of the correlation between the RNA" exact="viral" post="load and ARDS severity [27,46]. Although the typical MAS/sHLH"/>
 <result pre="between these two patterns is difficult. 3.3 Hyper-inflammation and severe" exact="respiratory" post="failure Although COVID-19 has numerous manifestations, lung injury and"/>
 <result pre="failure Although COVID-19 has numerous manifestations, lung injury and severe" exact="respiratory" post="failure (SRF) are more common than others. The cornerstone"/>
 <result pre="The cornerstone of this condition is MAS/sHLH or immune dysregulation." exact="Alveolar" post="macrophages secret IL-6 that cause overproduction of pro-inflammatory cytokines"/>
 <result pre="cytokines by monocytes, and dysregulation of lymphocytes, characterized by CD4" exact="lymphopenia" post="and subsequently B cell lymphopenia. In parallel, the absolute"/>
 <result pre="format of the cytokine storm, is trying to limit the" exact="infection" post="and overcome the virus; however, it leads to an"/>
 <result pre="may be beneficial to reverse the condition and treat the" exact="disease" post="[47]. Considering the pivotal role of IL-6 in CS,"/>
 <result pre="in COVID-19 patients with a severe condition [33]. There are" exact="limited" post="data about the effects of other immunosuppressive drugs, such"/>
 <result pre="vivo studies are recommended [31]. Due to the T cell" exact="lymphopenia" post="and reduced function, immunoglobulins produced by B cells represent"/>
 <result pre="and antibody production occurs by the first two weeks after" exact="infection" post="[48]. Like other infections, specific IgM is the first"/>
 <result pre="is the first defense to appear, and disappears after a" exact="short" post="time, but specific IgG remains a long-term defense against"/>
 <result pre="therapy, and after administration by the transfused plasma might neutralize" exact="viral" post="particles and activate the complement system, which could consequently"/>
 <result pre="and activate the complement system, which could consequently lead to" exact="viral" post="elimination. Despite its efficacy, this method has some difficulties"/>
 <result pre="concerns about causing an infection, and non-infectious transfusion reactions. Transfusion-induced" exact="infection" post="is rare in industrial countries (unlike poor countries) while"/>
 <result pre="while the latter is a global worry known as transfusion-related" exact="acute" post="lung injury (TRALI) and allergic reactions. As an important"/>
 <result pre="pandemic [57]. However, the lethality of this virus is much" exact="lower" post="than found in previous pandemics. What makes COVID-19 so"/>
 <result pre="is of the utmost importance to understand the pathophysiology of" exact="disease" post="and how the immune response to the pathogen affects"/>
 <result pre="the immune system is severely damaged and becomes inefficient by" exact="lymphopenia" post="and Tex, it tries to compensate by triggering the"/>
 <result pre="in COVID-19: a first perspectiveJ. Eur. Acad. Dermatol. Venereol.202010.1111/jdv.16387 4Giamarellos-BourboulisE.J.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.-E.KatsaounouP.NtaganouM.KyriakopoulouM.DimopoulosG.KoutsodimitropoulosI.VelissarisD.KoufargyrisP.KarageorgosA.KatriniK.LekakisV.LupseM.KotsakiA.RenierisG.TheodoulouD.PanouV.KoukakiE.KoulourisN.GogosC.KoutsoukouA.Complex" exact="Immune Dysregulation" post="in COVID-19 Patients with Severe Respiratory FailureCell Host Microbe202010.1016/j.chom.2020.04.009"/>
 <result pre="Acad. Dermatol. Venereol.202010.1111/jdv.16387 4Giamarellos-BourboulisE.J.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.-E.KatsaounouP.NtaganouM.KyriakopoulouM.DimopoulosG.KoutsodimitropoulosI.VelissarisD.KoufargyrisP.KarageorgosA.KatriniK.LekakisV.LupseM.KotsakiA.RenierisG.TheodoulouD.PanouV.KoukakiE.KoulourisN.GogosC.KoutsoukouA.Complex Immune Dysregulation in COVID-19 Patients with" exact="Severe" post="Respiratory FailureCell Host Microbe202010.1016/j.chom.2020.04.009 5Di GennaroF.PizzolD.MarottaC.AntunesM.RacalbutoV.VeroneseN.Coronavirus diseases (COVID-19) current"/>
 <result pre="Dermatol. Venereol.202010.1111/jdv.16387 4Giamarellos-BourboulisE.J.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.-E.KatsaounouP.NtaganouM.KyriakopoulouM.DimopoulosG.KoutsodimitropoulosI.VelissarisD.KoufargyrisP.KarageorgosA.KatriniK.LekakisV.LupseM.KotsakiA.RenierisG.TheodoulouD.PanouV.KoukakiE.KoulourisN.GogosC.KoutsoukouA.Complex Immune Dysregulation in COVID-19 Patients with Severe" exact="Respiratory" post="FailureCell Host Microbe202010.1016/j.chom.2020.04.009 5Di GennaroF.PizzolD.MarottaC.AntunesM.RacalbutoV.VeroneseN.Coronavirus diseases (COVID-19) current status"/>
 <result pre="perspectives: a narrative reviewInt. J. Environ. Res. Public Health1782020 6JahanshahluL.RezaeiN.Central" exact="Nervous System" post="Involvement in COVID-19 [published online ahead of print, 2020"/>
 <result pre="print, 2020 May 22]Arch. Med. Res.202010.1016/j.arcmed.2020.05.016 7InfantinoM.DamianiA.GobbiF.L.GrossiV.LariB.MacchiaD.Serological assays for SARS-CoV-2" exact="infectious" post="disease: benefits, limitations and perspectivesIsr. Med. Assoc. J.224202020321032286019 8JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.ACE2"/>
 <result pre="and perspectivesIsr. Med. Assoc. J.224202020321032286019 8JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.ACE2 receptor expression and severe" exact="acute" post="respiratory syndrome coronavirus infection depend on differentiation of human"/>
 <result pre="perspectivesIsr. Med. Assoc. J.224202020321032286019 8JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.ACE2 receptor expression and severe acute" exact="respiratory" post="syndrome coronavirus infection depend on differentiation of human airway"/>
 <result pre="Med. Assoc. J.224202020321032286019 8JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.ACE2 receptor expression and severe acute respiratory" exact="syndrome" post="coronavirus infection depend on differentiation of human airway epitheliaJ."/>
 <result pre="J.224202020321032286019 8JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.ACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epitheliaJ. Virol.79232005146141462116282461 9RezaeiN.COVID-19"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet39510223202050751332007143 12SaghazadehA.RezaeiN.Immune-epidemiological parameters of"/>
 <result pre="coronavirus - a perspectiveExpert. Rev. Clin. Immunol.165202046547010.1080/1744666X.2020.175095432237901 13YuanHaiCaoXiaoguangJiXiaoqiDuFangbingZhouXuanHeJiaweiXieYanghuZhuYuA Current Emerging" exact="Respiratory" post="Infection: Epidemiological and Clinical Characteristics, Diagnosis and Treatments of"/>
 <result pre="Treatments of COVID-19 (3/6/2020)Available at SSRN:202010.2139/ssrn.3551344 14FungS.Y.YuenK.S.YeZ.W.ChanC.P.JinD.Y.A tug-of-war between severe" exact="acute" post="respiratory syndrome coronavirus 2 and host antiviral defence: lessons"/>
 <result pre="of COVID-19 (3/6/2020)Available at SSRN:202010.2139/ssrn.3551344 14FungS.Y.YuenK.S.YeZ.W.ChanC.P.JinD.Y.A tug-of-war between severe acute" exact="respiratory" post="syndrome coronavirus 2 and host antiviral defence: lessons from"/>
 <result pre="COVID-19 (3/6/2020)Available at SSRN:202010.2139/ssrn.3551344 14FungS.Y.YuenK.S.YeZ.W.ChanC.P.JinD.Y.A tug-of-war between severe acute respiratory" exact="syndrome" post="coronavirus 2 and host antiviral defence: lessons from other"/>
 <result pre="pathogenesis and diagnosis of COVID-19J Pharm Anal.102202010210810.1016/j.jpha.2020.03.00132282863 18GroeneveldA.B.J.Vascular pharmacology of" exact="acute" post="lung injury and acute respiratory distress syndromeVasc. Pharmacol.3942002247256 19RokniM.GhasemiV.TavakoliZ.Immune"/>
 <result pre="COVID-19J Pharm Anal.102202010210810.1016/j.jpha.2020.03.00132282863 18GroeneveldA.B.J.Vascular pharmacology of acute lung injury and" exact="acute" post="respiratory distress syndromeVasc. Pharmacol.3942002247256 19RokniM.GhasemiV.TavakoliZ.Immune responses and pathogenesis of"/>
 <result pre="Pharm Anal.102202010210810.1016/j.jpha.2020.03.00132282863 18GroeneveldA.B.J.Vascular pharmacology of acute lung injury and acute" exact="respiratory" post="distress syndromeVasc. Pharmacol.3942002247256 19RokniM.GhasemiV.TavakoliZ.Immune responses and pathogenesis of SARS-CoV-2"/>
 <result pre="potential drivers of COVID-19: neutrophil extracellular trapsJ. Exp. Med.21762020 22LiG.FanY.LaiY.HanT.LiZ.ZhouP.Coronavirus" exact="infections" post="and immune responsesJ. Med. Virol.924202042443231981224 23CasilloG.M.MansourA.A.RaucciF.SavianoA.MascoloN.Jilani IqbalA.Could IL-17 represent"/>
 <result pre="new therapeutic target for the treatment and/or management of COVID-19-related" exact="respiratory" post="syndrome?Pharmacol. Res.202010479132302707 24ChiappelliF.CoViD-19 Immunopathology &amp;amp; ImmunotherapyBioinformation163202021922232308263 25DiaoB.WangC.TanY.ChenX.LiuY.NingL.Reduction and functional"/>
 <result pre="and functional exhaustion of T cells in patients with coronavirus" exact="disease" post="2019 (COVID-19)medRxiv20202020.02.18.20024364 26ZhangC.WuZ.LiJ.-W.ZhaoH.WangG.-Q.The cytokine release syndrome (CRS) of severe"/>
 <result pre="in patients with coronavirus disease 2019 (COVID-19)medRxiv20202020.02.18.20024364 26ZhangC.WuZ.LiJ.-W.ZhaoH.WangG.-Q.The cytokine release" exact="syndrome" post="(CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist"/>
 <result pre="of SARS-CoV-2 infectionâ€&quot;a review of immune changes in patients with" exact="viral" post="pneumoniaEmerging Microbes &amp;amp; Infections91202072773232196410 28FathiN.RezaeiN.Lymphopenia in COVID-19: Therapeutic opportunitiesCell"/>
 <result pre="COVID-19: Therapeutic opportunitiesCell Biol. Int.20201610.1002/cbin.11403 29SpezzaniV.PiunnoA.IselinH.-U.Benign COVID-19 in an immunocompromised" exact="cancer" post="patient - the case of a married coupleSwiss Med."/>
 <result pre="- the case of a married coupleSwiss Med. Wkly.202010.4414/smw.2020.20246 30GianfrancescoM.A.HyrichK.L.GossecL.Rheumatic" exact="disease" post="and COVID-19: initial data from the COVID-19 Global Rheumatology"/>
 <result pre="-19Arthritis Rheum.202010.1002/art.41285 33LiuB.LiM.ZhouZ.GuanX.XiangY.Can we use interleukin-6 (IL-6) blockade for coronavirus" exact="disease" post="2019 (COVID-19)-induced cytokine release syndrome (CRS)?J. Autoimmun.202010245232291137 34WangX.FangX.CaiZ.WuX.GaoX.MinJ.Comorbid chronic"/>
 <result pre="interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release" exact="syndrome" post="(CRS)?J. Autoimmun.202010245232291137 34WangX.FangX.CaiZ.WuX.GaoX.MinJ.Comorbid chronic diseases and acute organ injuries"/>
 <result pre="coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?J. Autoimmun.202010245232291137 34WangX.FangX.CaiZ.WuX.GaoX.MinJ.Comorbid" exact="chronic" post="diseases and acute organ injuries are strongly correlated with"/>
 <result pre="(COVID-19)-induced cytokine release syndrome (CRS)?J. Autoimmun.202010245232291137 34WangX.FangX.CaiZ.WuX.GaoX.MinJ.Comorbid chronic diseases and" exact="acute" post="organ injuries are strongly correlated with disease severity and"/>
 <result pre="chronic diseases and acute organ injuries are strongly correlated with" exact="disease" post="severity and mortality among COVID-19 patients: a systemic review"/>
 <result pre="correlated with disease severity and mortality among COVID-19 patients: a" exact="systemic" post="review and meta-analysisResearch (Wash D C)20202020240296132377638 35Guzman-FloresJ.M.Lopez-BrionesS.Cells of innate"/>
 <result pre="(Wash D C)20202020240296132377638 35Guzman-FloresJ.M.Lopez-BrionesS.Cells of innate and adaptive immunity in" exact="type 2" post="diabetes and obesityGac. Med. Mex.1484201238138922976756 36MeshkaniR.VakiliS.Tissue resident macrophages: key"/>
 <result pre="C)20202020240296132377638 35Guzman-FloresJ.M.Lopez-BrionesS.Cells of innate and adaptive immunity in type 2" exact="diabetes" post="and obesityGac. Med. Mex.1484201238138922976756 36MeshkaniR.VakiliS.Tissue resident macrophages: key players"/>
 <result pre="Mex.1484201238138922976756 36MeshkaniR.VakiliS.Tissue resident macrophages: key players in the pathogenesis of" exact="type 2" post="diabetes and its complicationsClin. Chim. Acta4622016778927570063 37YangJ.K.LinS.S.JiX.J.GuoL.M.Binding of SARS"/>
 <result pre="resident macrophages: key players in the pathogenesis of type 2" exact="diabetes" post="and its complicationsClin. Chim. Acta4622016778927570063 37YangJ.K.LinS.S.JiX.J.GuoL.M.Binding of SARS coronavirus"/>
 <result pre="of SARS coronavirus to its receptor damages islets and causes" exact="acute" post="diabetesActa Diabetol.473201019319919333547 38GuoW.LiM.DongY.Diabetes is a risk factor for the"/>
 <result pre="route: CD147-spike proteinbioRxiv202098834510.1101/2020.03.14.988345 41WanS.YiQ.FanS.LvJ.ZhangX.GuoL.LangC.XiaoQ.XiaoK.YiZ.QiangM.XiangJ.ZhangB.ChenY.GaoC.Relationships among lymphocyte subsets, cytokines, and the" exact="pulmonary" post="inflammation index in coronavirus (COVID-19) infected patientsBr. J. Haematol.189202042843710.1111/bjh.1665932297671"/>
 <result pre="42LiuJ.LiS.LiuJ.LiangB.WangX.WangH.Longitudinal characteristics of lymphocyte responses and cytokine profiles in the" exact="peripheral" post="blood of SARS-CoV-2 infected patientsmedRxiv20202020.02.16.20023671 43TufanA.AvanoÄŸlu GÃ¼lerA.Matucci-CerinicM.COVID-19, immune system"/>
 <result pre="Microbiol Immunol Infect.533202036837010.1016/j.jmii.2020.03.00532205092 45LiX.XuS.YuM.Risk factors for severity and mortality in" exact="adult" post="COVID-19 inpatients in Wuhanpublished online ahead of print, 2020"/>
 <result pre="Immunol.202010.1016/j.jaci.2020.04.006S0091-6749(20)30495-4 46McGonagleD.SharifK.Oâ€™ReganA.BridgewoodC.The role of cytokines including interleukin-6 in COVID-19 induced" exact="pneumonia" post="and macrophage activation syndrome-like diseaseAutoimmun. Rev.202010253732251717 47SaghazadehA.RezaeiN.Towards treatment planning"/>
 <result pre="Protocols in Microbiology5712020 49JuB.ZhangQ.GeX.WangR.YuJ.ShanS.Potent human neutralizing antibodies elicited by SARS-CoV-2" exact="infection" post="bioRxiv20202020.03.21.990770 50Md Insiat IslamR.Current drugs with potential for treatment"/>
 <result pre="blocking SARS-CoV-2 infectionNat. Commun.1112020225132366817 57MohamedK.RodrÃ­guez-RomÃ¡nE.RahmaniF.Borderless collaboration is needed for COVID-19-A" exact="disease" post="that knows no borderspublished online ahead of print, 2020"/>
 <result pre="on vaccine development against SARS-CoV-2Vaccines822020153 60MomtazmaneshSaraAll Together to Fight COVID-19The" exact="American" post="Journal of Tropical Medicine and Hygiene102620201181118332323644"/>
</results>
